The role of negative symptoms and cognitive dysfunction in schizophrenia outcome

被引:123
作者
Tamminga, CA [1 ]
Buchanan, RW [1 ]
Gold, JM [1 ]
机构
[1] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA
关键词
cognitive impairment; negative symptoms; schizophrenia;
D O I
10.1097/00004850-199803003-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Schizophrenia is a lifelong illness, with symptoms beginning in late adolescence/early adulthood and persisting throughout the rest of the patient's life. Positive psychotic symptoms may fluctuate during the course of the illness, but negative symptoms, especially primary negative symptoms, and cognitive dysfunction are relatively constant. The negative symptoms of schizophrenia are both primary (associated with the illness) and secondary (due to depression, neuroleptic-induced parkinsonism or acute psychosis). While secondary negative symptoms may be reduced by treating the causative agent, primary negative symptoms are viewed as enduring, persisting between psychotic episodes. Conventional antipsychotics treat the positive symptoms of schizophrenia, but they have little effect on primary negative and cognitive symptoms. Primary negative symptoms are often associated with poor premorbid function, the male sex, and low IQ (Intelligence Quotient). In addition, most studies find that negative symptoms are associated with a poor overall outcome. Several studies, including our own, have suggested that primary negative symptoms are functionally localized to the frontal and parietal cortices. These kinds of data raise the possibility that primary negative symptoms may have a pathophysiological basis distinct from positive psychosis. Cognitive impairment also appears to be a relatively independent aspect of schizophrenia. Impairment may be evident in a subtle form from early childhood, and often precedes the development of psychotic symptoms. Additional impairment accrues with the onset of psychotic illness with little evidence, in the vast majority of cases, of progression over the course of the illness. Cognitive impairment is only modestly related to psychotic symptom severity and type. However, the extent, and perhaps specific types of cognitive impairment, appear to be predictive of functional outcome. Int Clin Psychopharmacol 13 (suppl 3):S21-S26 (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:S21 / S26
页数:6
相关论文
共 46 条
[1]  
ADDINGTON J, 1993, J PSYCHIATR NEUROSCI, V18, P18
[2]   Differentiation of classical and novel antipsychotics using animal models [J].
Arnt, J ;
Skarsfeldt, T ;
Hyttel, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 :S9-S17
[3]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]  
BLANCHARD JJ, 1994, AM J PSYCHIAT, V151, P40
[6]   Negative symptoms: Diagnosis, treatment and prognosis [J].
Buchanan, RW ;
Gold, JM .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :3-11
[7]   THE COMPARATIVE EFFICACY AND LONG-TERM EFFECT OF CLOZAPINE TREATMENT ON NEUROPSYCHOLOGICAL TEST-PERFORMANCE [J].
BUCHANAN, RW ;
HOLSTEIN, C ;
BREIER, A .
BIOLOGICAL PSYCHIATRY, 1994, 36 (11) :717-725
[8]  
CANNON TD, 1994, ARCH GEN PSYCHIAT, V51, P651
[9]   SCHIZOPHRENIA [J].
CARPENTER, WT ;
BUCHANAN, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) :681-690
[10]   NEUROLEPTICS - EFFECTS ON NEUROPSYCHOLOGICAL FUNCTION IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
CASSENS, G ;
INGLIS, AK ;
APPELBAUM, PS ;
GUTHEIL, TG .
SCHIZOPHRENIA BULLETIN, 1990, 16 (03) :477-499